Avexxin concludes second phase I/IIA study in patients suffering from mild-to-moderat

[News]

Avexxin AS, a therapeutic company focusing on the discovery and development of novel small molecule therapeutics for patients suffering from chronic inflammatory conditions, announces the completion of a second phase I/IIa study showing Proof-of-Concept in man.

More... (http://www.news-medical.net/news/20150702/Avexxin-concludes-second-phase-IIIA-study-in-patients-suffering-from-mild-to-moderate-psoriasis.aspx)